# CMV-specific immune monitoring test

## QuantiFERON®-CMV



"How do I know which of my transplant patients are at risk of CMV disease?"

QIAGEN®

www.QuantiFERON.com

## Which transplant patients are at risk of CMV disease post-prophylaxis?

Current immunosuppressive therapies used to prevent the rejection of a transplanted organ have detrimental effects upon the T-lymphocytes and cell-mediated immune responses in solid organ transplant (SOT) recipients. These patients have an increased susceptibility to viral infections post-transplant.[2, 3] Approximately half of these patients show signs of active Cytomegalovirus (CMV) infection (ie. viral replication) after completion of antiviral prophylaxis.[1]

Consequently, CMV-associated morbidity and mortality in transplant recipients are very high.[3–5] Infection can result not only in organ-specific conditions affecting the brain, lungs, and liver, but also in opportunistic infections, increased allograft rejection, and patient death. These CMV-related complications add an estimated 49% to the cost of transplant care.[6]

The immune status of the transplant recipient can influence the (re)activation of CMV in transplant recipients. A specific cytokine marker for cellular immune responses, interferon-gamma (IFN-γ) plays a key role.[7, 8] Secreted from CMV-specific T-cells in response to antigens associated with CMV infection,[8, 9] IFN-γ levels may indicate a patient's overall level of cell-mediated immunity.

**Cytomegalovirus (CMV) is the most common and problematic viral infection in solid organ transplant recipients.**

## How can QuantiFERON-CMV help identify at-risk patients?

QuantiFERON-CMV uses specialized (1 mL) blood collection tubes that are coated with peptides simulating $CD8^+$-specific epitopes of CMV proteins, along with negative and positive control tubes. Stimulation of CD8+ T-cells in whole blood with the CMV peptides results in the production of IFN-γ in infected individuals. An enzyme-linked immunosorbent assay (ELISA) is then used to measure the amount of IFN-γ present in plasma from each of the three tubes (Nil control, CMV-antigen, and Mitogen control). A robust IFN-γ response in the CMV antigen tube is indicative of immunity to CMV.[11]

## Immunity to CMV during Post-Transplantation prophylaxis




**Figure 1. A theoretical model of QuantiFERON-CMV responses in a post-transplant setting during and/or following prophylaxis and immune suppression.**

## Freedom from CMV-related events

Patients who have a cellular immune response to CMV at the end of prophylaxis have a significantly lower risk of developing CMV disease than those who do not have a detectable immune response. This indicates that QuantiFERON-CMV may predict the development of late-onset CMV disease in transplant recipients. [8, 10–13]




**Figure 2. Time to development of CMV disease in patients with a QuantiFERON-CMV Reactive result versus a QuantiFERON-CMV Non-Reactive result at the end of prophylaxis.** Data reproduced from Kumar *et al.*[11]

**Patients with a positive QuantiFERON-CMV test remain free from CMV disease significantly more often and for longer than patients with a negative QuantiFERON-CMV after cessation of antiviral prophylaxis.**

## Clinical confidence

QuantiFERON-CMV may assist[13] your ability to:

- Predict the risk of new and recurrent CMV disease
- Guide therapeutic decision-making
- Improve patient health.

QuantiFERON-CMV is not a direct test for determining CMV infection and should not solely be used to exclude CMV infection.

**The accuracy, efficacy, and utility of QuantiFERON-CMV for monitoring CMV-related changes in cell-mediated immunity has been demonstrated in numerous studies.**[8, 10–13]

## New international consensus guidelines on the management of CMV in SOT

The recently-published "International Consensus Guidelines on the Management of Cytomegalovirus in solid organ transplantation" [14] suggest that an ideal immune monitoring assay should:

- Assess the quantity and function of a transplant recipient's $CD4^+$ and $CD8^+$ T-cells
- Be able to measure interferon-γ
- Be simple to perform, cost-effective, and reproducible
- Have a rapid turnaround time
- Allow for specimens to be easily shipped to specialized referral laboratories.

QuantiFERON-CMV meets virtually all the criteria specified by the guidelines above and is the only standardized, commercially-available immune monitoring assay that is specific for CMV.[14]

**Studies now highlight that monitoring a patient's level of cellular immunity to CMV using QuantiFERON-CMV could help guide the optimal duration of costly anti-CMV prophylaxis in high-risk patients.**[8, 10, 11, 13–16]

# About QuantiFERON® Technology




**Figure 3. Diagram illustrating the QuantiFERON-CMV process.**

**QuantiFERON Technology is a unique approach to disease detection and monitoring—the only *in vitro* diagnostic technology available for detection of cell-mediated immune responses from whole blood samples.**

Individuals exposed to CMV and other diseases have specific T-cell lymphocytes in their blood. These T-cells are a memory bank of an individual's immune system, recognizing antigens to which the T-cells have been previously exposed. When a disease-specific antigen is combined with the blood of an individual who has been exposed to that disease, a rapid re-stimulation of the T-cells with specific memory of that antigen occurs. These antigen-specific T-cells respond by secreting IFN-γ, which can be measured as a specific marker of immune response against that disease antigen.

QuantiFERON-CMV is not US FDA-approved and is limited to research use only in the United States.

QuantiFERON-CMV is CE Marked for commercial use in Europe.


**References**

**1.** Paya C, *et al. Am J Transpl. 2004; 4:611–20.* **2.** Smyth RL, *et al. Transplantation. 1991; 52:480–2.* **3.** Boeckh M , *Nichols WG. Herpes. 2003; 10:12–16.* **4.** Gandhi MK, *Khanna R. Lancet Infect Dis. 2004; 4:725–38.* **5.** Humar A, *et al. Transplantation. 2000; 70:310–3.* **6.** Kim WR, *et al. Transplantation. 2000; 69:357–61.* **7.** Sylwester AW, *et al. J Exp Med. 2005; 202:673–85.* **8.** Walker S, *et al. Transpl Infect Dis. 2007; 9:165–70.* **9.** Westall G, *et al. Am J Transpl. 2006; 6:577–84.* **10.** Westall GP, *et al. Am J Transpl. 2008; 8:1749–54.* **11.** Kumar D, *et al. Am J Transpl. 2009; 9:1214–22.* **12.** Singh N. *J Clin Virol. 2006; 35:474–7.* **13.** Danziger-Isakov LA, *et al. Transplantation. 2003; 75:1538–43.* **14.** Kotton CN, *et al. Transplantation 2010; 89.* **15.** Danziger-Isakov L, *Heeger PS. Am J Transpl. 2009; 9:1214–22.* **16.** Crough T, Khanna R. *Clin Micro Reviews. 2009; 22:76–98.*





**Cellestis, a QIAGEN Company**

**Asia/Pacific** ▪ QIAGEN Singapore PTE Ltd ▪ +65 6854 8100 ▪ asiapac@cellestis.com
**Australia/New Zealand** ▪ Cellestis Ltd ▪ +61 3 9840 9800 ▪ orders-au@qiagen.com
**Europe/Middle East/Africa** ▪ QIAGEN GmbH ▪ +49 2103 291 2000 ▪ orders-de@qiagen.com
**Japan/Korea** ▪ QIAGEN KK ▪ +81 3 6890 7300 ▪ jp.kr@cellestis.com
**North America/South America** ▪ Cellestis Inc ▪ +1 661 775 7480 ▪ customer.service@cellestis.com